As with other anticoagulants, the main concern is increased bleed risk. The risk of hemorrhage may increase with decreased renal function, body mass less than 50 kg, and moderate to severe hepatic function.
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Apixaban | Apixaban may increase the anticoagulant activities of Fondaparinux. |
| Dabigatran etexilate | Dabigatran etexilate may increase the anticoagulant activities of Fondaparinux. |
| Dasatinib | The risk or severity of bleeding and hemorrhage can be increased when Dasatinib is combined with Fondaparinux. |
| Deferasirox | The risk or severity of gastrointestinal bleeding can be increased when Fondaparinux is combined with Deferasirox. |
| Ursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Ursodeoxycholic acid. |
| Glycochenodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Glycochenodeoxycholic Acid. |
| Cholic Acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Cholic Acid. |
| Glycocholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Glycocholic acid. |
| Deoxycholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Deoxycholic acid. |
| Taurocholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Taurocholic acid. |
| Obeticholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Obeticholic acid. |
| Chenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Chenodeoxycholic acid. |
| Taurochenodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Taurochenodeoxycholic acid. |
| Tauroursodeoxycholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Tauroursodeoxycholic acid. |
| Bamet-UD2 | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Bamet-UD2. |
| Dehydrocholic acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Dehydrocholic acid. |
| Hyodeoxycholic Acid | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Hyodeoxycholic Acid. |
| Edoxaban | The risk or severity of bleeding can be increased when Edoxaban is combined with Fondaparinux. |
| Ibrutinib | The risk or severity of bleeding and hemorrhage can be increased when Ibrutinib is combined with Fondaparinux. |
| Obinutuzumab | The risk or severity of bleeding and hemorrhage can be increased when Fondaparinux is combined with Obinutuzumab. |
| Rivaroxaban | Fondaparinux may increase the anticoagulant activities of Rivaroxaban. |
| Sugammadex | The risk or severity of bleeding and hemorrhage can be increased when Fondaparinux is combined with Sugammadex. |
| Tibolone | Tibolone may increase the anticoagulant activities of Fondaparinux. |
| Tipranavir | The risk or severity of bleeding and hemorrhage can be increased when Tipranavir is combined with Fondaparinux. |
| Urokinase | Urokinase may increase the anticoagulant activities of Fondaparinux. |
| Vitamin E | Vitamin E may increase the anticoagulant activities of Fondaparinux. |
| Vorapaxar | The risk or severity of bleeding and hemorrhage can be increased when Vorapaxar is combined with Fondaparinux. |
| Ginkgo biloba | Ginkgo biloba may increase the anticoagulant activities of Fondaparinux. |
| Ifosfamide | The risk or severity of bleeding can be increased when Ifosfamide is combined with Fondaparinux. |
| Quinine | The therapeutic efficacy of Fondaparinux can be increased when used in combination with Quinine. |
| Quinidine | The therapeutic efficacy of Fondaparinux can be increased when used in combination with Quinidine. |
| Tamoxifen | The risk or severity of bleeding can be increased when Tamoxifen is combined with Fondaparinux. |
| Toremifene | The risk or severity of bleeding can be increased when Toremifene is combined with Fondaparinux. |
| Pentoxifylline | The therapeutic efficacy of Fondaparinux can be increased when used in combination with Pentoxifylline. |
| Pentosan polysulfate | Pentosan polysulfate may increase the anticoagulant activities of Fondaparinux. |
| Levocarnitine | The therapeutic efficacy of Fondaparinux can be increased when used in combination with Levocarnitine. |
| Diethylstilbestrol | Diethylstilbestrol may decrease the anticoagulant activities of Fondaparinux. |
| Chlorotrianisene | Chlorotrianisene may decrease the anticoagulant activities of Fondaparinux. |
| Conjugated estrogens | Conjugated estrogens may decrease the anticoagulant activities of Fondaparinux. |
| Mestranol | The risk or severity of adverse effects can be increased when Mestranol is combined with Fondaparinux. |
| Estrone sulfate | Estrone sulfate may decrease the anticoagulant activities of Fondaparinux. |
| Quinestrol | Quinestrol may decrease the anticoagulant activities of Fondaparinux. |
| Hexestrol | Hexestrol may decrease the anticoagulant activities of Fondaparinux. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Fondaparinux. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Fondaparinux. |
| Polyestradiol phosphate | Polyestradiol phosphate may decrease the anticoagulant activities of Fondaparinux. |
| Esterified estrogens | Esterified estrogens may decrease the anticoagulant activities of Fondaparinux. |
| Zeranol | Zeranol may decrease the anticoagulant activities of Fondaparinux. |
| Equol | Equol may decrease the anticoagulant activities of Fondaparinux. |
| Methallenestril | Methallenestril may decrease the anticoagulant activities of Fondaparinux. |
| Epimestrol | Epimestrol may decrease the anticoagulant activities of Fondaparinux. |
| Moxestrol | Moxestrol may decrease the anticoagulant activities of Fondaparinux. |
| Estradiol acetate | Estradiol acetate may decrease the anticoagulant activities of Fondaparinux. |
| Estradiol benzoate | Estradiol benzoate may decrease the anticoagulant activities of Fondaparinux. |
| Estradiol cypionate | Estradiol cypionate may decrease the anticoagulant activities of Fondaparinux. |
| Estradiol valerate | Estradiol valerate may decrease the anticoagulant activities of Fondaparinux. |
| Biochanin A | Biochanin A may decrease the anticoagulant activities of Fondaparinux. |
| Formononetin | Formononetin may decrease the anticoagulant activities of Fondaparinux. |
| Estriol | Estriol may decrease the anticoagulant activities of Fondaparinux. |
| Limaprost | The risk or severity of adverse effects can be increased when Limaprost is combined with Fondaparinux. |
| Icosapent | The risk or severity of bleeding and hemorrhage can be increased when Icosapent is combined with Fondaparinux. |
| Mesalazine | The risk or severity of bleeding can be increased when Mesalazine is combined with Fondaparinux. |
| Indomethacin | The risk or severity of bleeding and hemorrhage can be increased when Indomethacin is combined with Fondaparinux. |
| Nabumetone | The risk or severity of bleeding and hemorrhage can be increased when Nabumetone is combined with Fondaparinux. |
| Ketorolac | The risk or severity of bleeding and hemorrhage can be increased when Ketorolac is combined with Fondaparinux. |
| Tenoxicam | The risk or severity of bleeding and hemorrhage can be increased when Tenoxicam is combined with Fondaparinux. |
| Celecoxib | The risk or severity of bleeding and hemorrhage can be increased when Celecoxib is combined with Fondaparinux. |
| Tolmetin | The risk or severity of bleeding and hemorrhage can be increased when Tolmetin is combined with Fondaparinux. |
| Rofecoxib | The risk or severity of bleeding and hemorrhage can be increased when Rofecoxib is combined with Fondaparinux. |
| Piroxicam | The risk or severity of bleeding and hemorrhage can be increased when Piroxicam is combined with Fondaparinux. |
| Fenoprofen | The risk or severity of bleeding and hemorrhage can be increased when Fenoprofen is combined with Fondaparinux. |
| Valdecoxib | The risk or severity of bleeding and hemorrhage can be increased when Valdecoxib is combined with Fondaparinux. |
| Diclofenac | The risk or severity of bleeding and hemorrhage can be increased when Diclofenac is combined with Fondaparinux. |
| Sulindac | The risk or severity of bleeding and hemorrhage can be increased when Sulindac is combined with Fondaparinux. |
| Flurbiprofen | The risk or severity of bleeding and hemorrhage can be increased when Flurbiprofen is combined with Fondaparinux. |
| Etodolac | The risk or severity of bleeding and hemorrhage can be increased when Etodolac is combined with Fondaparinux. |
| Mefenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Mefenamic acid is combined with Fondaparinux. |
| Naproxen | The risk or severity of bleeding and hemorrhage can be increased when Naproxen is combined with Fondaparinux. |
| Sulfasalazine | The risk or severity of bleeding and hemorrhage can be increased when Sulfasalazine is combined with Fondaparinux. |
| Phenylbutazone | The risk or severity of bleeding and hemorrhage can be increased when Phenylbutazone is combined with Fondaparinux. |
| Meloxicam | The risk or severity of bleeding and hemorrhage can be increased when Meloxicam is combined with Fondaparinux. |
| Carprofen | The risk or severity of bleeding and hemorrhage can be increased when Carprofen is combined with Fondaparinux. |
| Diflunisal | The risk or severity of bleeding and hemorrhage can be increased when Diflunisal is combined with Fondaparinux. |
| Salicylic acid | The risk or severity of bleeding and hemorrhage can be increased when Salicylic acid is combined with Fondaparinux. |
| Meclofenamic acid | The risk or severity of bleeding and hemorrhage can be increased when Meclofenamic acid is combined with Fondaparinux. |
| Oxaprozin | The risk or severity of bleeding and hemorrhage can be increased when Oxaprozin is combined with Fondaparinux. |
| Ketoprofen | The risk or severity of bleeding and hemorrhage can be increased when Ketoprofen is combined with Fondaparinux. |
| Balsalazide | The risk or severity of bleeding and hemorrhage can be increased when Balsalazide is combined with Fondaparinux. |
| Olsalazine | The risk or severity of bleeding can be increased when Olsalazine is combined with Fondaparinux. |
| Lumiracoxib | The risk or severity of bleeding and hemorrhage can be increased when Lumiracoxib is combined with Fondaparinux. |
| Magnesium salicylate | The risk or severity of bleeding and hemorrhage can be increased when Magnesium salicylate is combined with Fondaparinux. |
| Salsalate | The risk or severity of bleeding and hemorrhage can be increased when Salsalate is combined with Fondaparinux. |
| Choline magnesium trisalicylate | The risk or severity of bleeding and hemorrhage can be increased when Choline magnesium trisalicylate is combined with Fondaparinux. |
| Antrafenine | The risk or severity of bleeding and hemorrhage can be increased when Antrafenine is combined with Fondaparinux. |
| Aminophenazone | The risk or severity of bleeding and hemorrhage can be increased when Aminophenazone is combined with Fondaparinux. |
| Antipyrine | The risk or severity of bleeding and hemorrhage can be increased when Antipyrine is combined with Fondaparinux. |
| Tiaprofenic acid | The risk or severity of bleeding and hemorrhage can be increased when Tiaprofenic acid is combined with Fondaparinux. |
| Etoricoxib | The risk or severity of bleeding and hemorrhage can be increased when Etoricoxib is combined with Fondaparinux. |
| Taxifolin | The risk or severity of bleeding and hemorrhage can be increased when Taxifolin is combined with Fondaparinux. |
| Oxyphenbutazone | The risk or severity of bleeding and hemorrhage can be increased when Oxyphenbutazone is combined with Fondaparinux. |